MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Charles River Laboratories International Inc

Fermé

SecteurSoins de santé

173.53 -0.81

Résumé

Variation du prix de l'action

24h

Actuel

Min

172.69

Max

173.66

Chiffres clés

By Trading Economics

Revenu

-332M

-277M

Ventes

-11M

994M

Marge bénéficiaire

-27.816

Employés

18,300

EBITDA

730K

198M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+18.4% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-78M

7.9B

Ouverture précédente

174.34

Clôture précédente

173.53

Sentiment de l'Actualité

By Acuity

50%

50%

141 / 349 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 avr. 2026, 04:27 UTC

Principaux Événements d'Actualité

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

5 avr. 2026, 23:55 UTC

Market Talk

Gold Falls Amid Dollar Strength, Inflation Worries -- Market Talk

5 avr. 2026, 23:45 UTC

Market Talk

Nikkei May Decline on Concerns About Energy Costs -- Market Talk

5 avr. 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 avr. 2026, 23:42 UTC

Market Talk

China's Consumer Inflation Likely Eased in March -- Market Talk

5 avr. 2026, 23:38 UTC

Market Talk
Principaux Événements d'Actualité

Oil Futures Rise Amid Increased Supply Disruption Concerns -- Market Talk

5 avr. 2026, 12:57 UTC

Principaux Événements d'Actualité

Some Italian Airports Report Jet-Fuel Shortages -- WSJ

3 avr. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 avr. 2026, 18:30 UTC

Principaux Événements d'Actualité

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 avr. 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 avr. 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 avr. 2026, 17:44 UTC

Acquisitions, Fusions, Rachats

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 avr. 2026, 16:50 UTC

Principaux Événements d'Actualité

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 avr. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 avr. 2026, 16:12 UTC

Résultats

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 avr. 2026, 15:56 UTC

Market Talk
Principaux Événements d'Actualité

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 avr. 2026, 15:56 UTC

Market Talk
Principaux Événements d'Actualité

Global Equities Roundup: Market Talk

3 avr. 2026, 15:56 UTC

Market Talk
Principaux Événements d'Actualité

Global Forex and Fixed Income Roundup: Market Talk

3 avr. 2026, 15:20 UTC

Principaux Événements d'Actualité

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 avr. 2026, 15:08 UTC

Acquisitions, Fusions, Rachats

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 avr. 2026, 14:11 UTC

Market Talk
Principaux Événements d'Actualité

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 avr. 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 avr. 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 avr. 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3 avr. 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 avr. 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 avr. 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 avr. 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3 avr. 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 avr. 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

18.4% hausse

Prévisions sur 12 Mois

Moyen 205.89 USD  18.4%

Haut 265 USD

Bas 175 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

8

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

117.16 / 144.77Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

141 / 349Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat